---
figid: PMC8512456__tlcr-10-09-3823-f2
figtitle: 'Tumor immune microenvironment in epidermal growth factor receptor-mutated
  non-small cell lung cancer before and after epidermal growth factor receptor tyrosine
  kinase inhibitor treatment: a narrative review'
organisms:
- Homo sapiens
- Mus musculus
- NA
pmcid: PMC8512456
filename: tlcr-10-09-3823-f2.jpg
figlink: /pmc/articles/PMC8512456/figure/f2/
number: F2
caption: Cytokines in the TIME of EGFR-mutant lung cancer. EGFR-TKIs can induce PD-L1
  protein degradation via the GSK3β and ubiquitin protease pathways, contributing
  to T cell activation. EGFR mutation can up-regulate amphiregulin (AREG), which maintains
  Treg suppressive function via the EGFR/GSK-3β/Foxp3 axis. Axl kinase, genes encoding
  immune checkpoint molecules (CD274, CTLA4), chemokine receptors (CXCR4, CXCR6),
  or chemokines (CXCL16) are overexpressed in EGFR-TKI resistant NSCLC. Overexpression
  of hepatocyte growth factor (HGF) induces EMT via the HGF-MET pathway, resulting
  in EGFR-TKI resistance. PD-L1 induces EMT via the TGF-β/Smad3 pathway. Activation
  of the TGF-β/Smad2 pathway can also induce EMT by increasing the expression of CXCR4.
  Furthermore, TGF-β can induce EMT and EGFR-TKI resistance by increasing the expression
  of PCKα, activation of the Akt-ERK pathway, increasing MIG6 expression, and decreasing
  PTEN expression. Adrenergic β2 receptors can induce EGFR-TKI resistance by increasing
  the expression of IL-6. RNF25 promotes EGFR-TKI resistance by inducing ERK reactivation
  by the expression of IL6 via the NK-κB signaling pathway. ILK, SHP, SPP1, and IGF1R
  are highly expressed in EGFR-TKI-resistant NSCLC. CXCR7 can promote EGFR-TKI-resistance
  by the EMT of tumor cells through activation of the MAPK-ERK pathway via β-arrestin.
  TIME, tumor immune microenvironment; EGFR, epidermal growth factor receptor; TKI,
  tyrosine kinase inhibitor; NSCLC, non-small cell lung cancer; EMT, epithelial mesenchymal
  transition.
papertitle: 'Tumor immune microenvironment in epidermal growth factor receptor-mutated
  non-small cell lung cancer before and after epidermal growth factor receptor tyrosine
  kinase inhibitor treatment: a narrative review.'
reftext: Lihui Liu, et al. Transl Lung Cancer Res. 2021 Sep;10(9):3823-3839.
year: '2021'
doi: 10.21037/tlcr-21-572
journal_title: Translational Lung Cancer Research
journal_nlm_ta: Transl Lung Cancer Res
publisher_name: AME Publishing Company
keywords: Non-small cell lung cancer (NSCLC) | epidermal growth factor receptor mutation
  (EGFR mutation) | epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)
  | tumor immune microenvironment (TIME)
automl_pathway: 0.9266322
figid_alias: PMC8512456__F2
figtype: Figure
organisms_ner:
- Homo sapiens
- Mus musculus
redirect_from: /figures/PMC8512456__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8512456__tlcr-10-09-3823-f2.html
  '@type': Dataset
  description: Cytokines in the TIME of EGFR-mutant lung cancer. EGFR-TKIs can induce
    PD-L1 protein degradation via the GSK3β and ubiquitin protease pathways, contributing
    to T cell activation. EGFR mutation can up-regulate amphiregulin (AREG), which
    maintains Treg suppressive function via the EGFR/GSK-3β/Foxp3 axis. Axl kinase,
    genes encoding immune checkpoint molecules (CD274, CTLA4), chemokine receptors
    (CXCR4, CXCR6), or chemokines (CXCL16) are overexpressed in EGFR-TKI resistant
    NSCLC. Overexpression of hepatocyte growth factor (HGF) induces EMT via the HGF-MET
    pathway, resulting in EGFR-TKI resistance. PD-L1 induces EMT via the TGF-β/Smad3
    pathway. Activation of the TGF-β/Smad2 pathway can also induce EMT by increasing
    the expression of CXCR4. Furthermore, TGF-β can induce EMT and EGFR-TKI resistance
    by increasing the expression of PCKα, activation of the Akt-ERK pathway, increasing
    MIG6 expression, and decreasing PTEN expression. Adrenergic β2 receptors can induce
    EGFR-TKI resistance by increasing the expression of IL-6. RNF25 promotes EGFR-TKI
    resistance by inducing ERK reactivation by the expression of IL6 via the NK-κB
    signaling pathway. ILK, SHP, SPP1, and IGF1R are highly expressed in EGFR-TKI-resistant
    NSCLC. CXCR7 can promote EGFR-TKI-resistance by the EMT of tumor cells through
    activation of the MAPK-ERK pathway via β-arrestin. TIME, tumor immune microenvironment;
    EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; NSCLC,
    non-small cell lung cancer; EMT, epithelial mesenchymal transition.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CD274
  - FOXP3
  - IL6
  - CXCL1
  - EGFR
  - CXCL2
  - AXL
  - ERVK-8
  - ERVK-10
  - ERVK-9
  - ERVK-21
  - ERVK-18
  - ERVK-25
  - ERVK-24
  - ERVK-19
  - ILK
  - CTLA4
  - GEN1
  - CXCR6
  - CXCL6
  - CXCR4
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - STAT3
  - PTEN
  - PTPN11
  - MAPK3
  - MAPK1
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - CXCL8
  - IGF1R
  - ITK
  - SLC22A3
  - ACKR3
  - SMAD3
  - RNF25
  - ADRB2
  - ARRB2
  - SMAD2
  - NFKB1
  - EPHB2
  - MIR762
  - SPP1
  - CXXC1
  - SGPP1
  - Cd274
  - Foxp3
  - Il6
  - Cxcl1
  - Egfr
  - Cxcl2
  - Axl
  - Ilk
  - Ctla4
  - Cxcr6
  - Cxcl5
  - Cxcr4
  - Hc
  - Stat3
  - Pten
  - Ptpn11
  - Mapk3
  - Mapk1
  - Cxcl15
  - Igf1r
  - Itk
  - Slc22a3
  - Ackr3
  - Smad3
  - Rnf25
  - Smad2
  - Nfkb1
  - Ephb2
  - Mir762
  - Spp1
  - Sgpp1
---
